| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
ZUG, Switzerland, March 4, 2024 – MoonLake Immunotherapeutics (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis suppurativa (HS), will be presented in a late breaking oral session on March 10 at 14:00 PST at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 8-12, in San Diego, California.
Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: "We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation. Hidradenitis suppurativa is a severely debilitating chronic skin condition and the data will showcase the therapeutic effect of maintenance treatment with our Nanobody® sonelokimab."
The oral presentation titled "Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial" will be presented by Professor Brian Kirby MD, FRCPI, Department of Dermatology, St. Vincent's University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland. The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
Key members of the MoonLake team, including the executive leadership team, will attend AAD.
In June 2023, MoonLake announced that the MIRA trial achieved a landmark milestone with positive top-line 12-week data using HiSCR75 as the primary endpoint and later presented the data at a late-breaking session at the European Academy of Dermatology and Venereology Congress in October. This was followed by an announcement in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS.
Sonelokimab is not yet approved for use in any indication.
Posted In: MLTX
